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Summary
 
The chemokine receptor CXCR4 is the major coreceptor used for cellular entry by T cell–
tropic human immunodeficiency virus (HIV)-1 strains, whereas CCR5 is used by macrophage
(M)-tropic strains. Here we show that a small-molecule inhibitor, ALX40-4C, inhibits HIV-1
envelope (Env)-mediated membrane fusion and viral entry directly at the level of coreceptor
use. ALX40-4C inhibited HIV-1 use of the coreceptor CXCR4 by T- and dual-tropic HIV-1
strains, whereas use of CCR5 by M- and dual-tropic strains was not inhibited. Dual-tropic vi-
ruses capable of using both CXCR4 and CCR5 were inhibited by ALX40-4C only when cells
expressed CXCR4 alone. ALX40-4C blocked stromal-derived factor (SDF)-1
 
a
 
–mediated ac-
tivation of CXCR4 and binding of the monoclonal antibody 12G5 to cells expressing
CXCR4. Overlap of the ALX40-4C binding site with that of 12G5 and SDF implicates direct
blocking of Env interactions, rather than downregulation of receptor, as the mechanism of in-
hibition. Thus, ALX40-4C represents a small-molecule inhibitor of HIV-1 infection that acts
directly against a chemokine receptor at the level of Env-mediated membrane fusion.
 
H
 
IV-1 infection is characterized by massive virus pro-
duction, calculated to be on the order of 10
 
9
 
 virus
particles per day (1, 2). New combination chemotherapies
have lead to dramatic and sustained reductions of viral load
in many individuals, often to undetectable levels (3). How-
ever, these therapies require rigorous adherence to a com-
plicated drug regimen, are expensive, and can cause signifi-
cant side effects. These factors, coupled with the likelihood
that resistant viruses may emerge with time, argue for the
continued development of compounds that can block
HIV-1 replication at multiple levels of the viral life cycle.
Recent advances have shown that certain chemokine re-
ceptors, in conjunction with CD4, play a critical role in
enabling HIV-1 to enter a cell. Macrophage (M)-tropic vi-
rus strains use the chemokine receptor CCR5 to enter cells
(4–8), whereas the T cell line–tropic viruses that may
emerge years after infection use the chemokine receptor
CXCR4 (9).
The importance of chemokine receptors for virus infec-
tion in vivo is shown by the fact that individuals who lack
CCR5 are highly resistant to virus infection (10–12). The
central role of CCR5 in viral transmission and the lack of
obvious consequences associated with loss of CCR5 func-
tion suggests that chemokine receptors may represent in-
variant cellular targets for antiviral agents. Indeed, the natu-
ral ligands to CCR5 and CXCR4 inhibit virus infection in
vitro (5, 13–16), and the ligands for CCR5 (RANTES,
MIP-1
 
a
 
, MIP-1
 
b
 
) have been identified as major antiretro-
viral factors secreted by CD8
 
1
 
 T cells (16). Chemically
modified forms of RANTES inhibit HIV-1 entry more
potently than wild-type RANTES, indicating that more
effective chemokines can be developed (17, 18). However,
chemokines (8–10-kD proteins) are subject to the limita-
tions of any structurally complex, labile protein in terms of
therapeutic potential. Therefore, small molecule inhibitors
of chemokine receptor use are desirable. In this study, we
demonstrate that a small-molecule inhibitor of HIV-1 in-
fection can be developed that prevents viral entry by di-
rectly targeting the chemokine receptor CXCR4.
 
Materials and Methods
 
Reagents.
 
All cells were maintained in DMEM or RPMI-1640
containing 10% FCS. Vaccinia viruses encoding HIV-1 envelopes
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(Envs) included vSC60 (BH8; reference 19), vCB28 (JR-FL; ref-
erence 19), and vBD3 (89.6; reference 7). Primary virus strains
were described previously (20), and infection was monitored by
p24 production. The development and synthesis of ALX40-4C
has been described previously (21).
 
Infection and Fusion Assays.
 
293T cells were transfected with
plasmids encoding Env and the NL4-3 luciferase virus backbone
(pNL-Luc-E
 
2
 
R
 
2
 
; reference 22). Plasmids encoding the HIV-1
Envs ADA, HXB2, and NL4-3 were provided by John Moore
(Aaron Diamond AIDS Research Center, New York), and pNL-
Luc-E
 
2
 
R
 
2
 
 was provided by Ned Landau (Aaron Diamond AIDS
Research Center). Cells were infected with 100 
 
m
 
l of viral super-
natant in a total volume of 500 
 
m
 
l with 4 
 
m
 
g/ml polybrene. Cells
were lysed 4 d after infection and 50 
 
m
 
l of the resulting lysate was
assayed for luciferase activity. ALX40-4C was added to cells 1 h
before infection. Virus production from PBMCs and MT2 cell
infections was assessed in culture supernatant by p24 content
(Coulter Corp., Miami, FL).
To quantitate cell–cell fusion events, we used a luciferase-
based gene reporter assay (7, 23). PA317-T4 cells were trans-
fected with T7 luciferase and coreceptor constructs by CaPO
 
4
 
transfection, and incubated at 37
 
8
 
C overnight. T7 RNA poly-
merase and Env proteins were introduced into effector 293T cells
by infection with recombinant vaccinia viruses and incubation at
32
 
8
 
C overnight in the presence of rifampicin. Target and effector
cells were mixed in 24-well plates at 37
 
8
 
C in the presence of ara-C
and rifampicin. After 5 h, cells were lysed and assayed for luciferase
activity. For inhibition, 10 
 
m
 
M ALX40-4C was preincubated
with target cells 30 min before addition of effector cells.
 
Ca
 
2
 
1
 
 Mobilization Assays.
 
Response to ligand was deter-
mined in the human T cell line SupT1. Cells were incubated in
media containing 2.5 
 
m
 
M Fura-2/AM (Molecular Probes Inc.,
Eurgene, OR) at 37
 
8
 
C in the dark for 1 h. Cells were allowed to
efflux for 15 min in PBS before resuspension in Delbecco’s PBS
containing calcium and magnesium at 2 
 
3
 
 10
 
6
 
 cells/ml. Ca
 
2
 
1
 
mobilization was measured in an Aminco-Bowman luminescence
spectrometer.
 
Flow Cytometry.
 
Quantitation of surface molecules on SupT1,
PM1, and 293T cells was performed by washing with 2% fetal
bovine serum (FBS)/PBS, blocking with 10% normal rabbit sera
in PBS, staining with 10 
 
m
 
g/ml of the indicated monoclonal anti-
body in 100 
 
m
 
l for 30 min, and detecting with an FITC-conju-
gated second antibody. For blocking, ALX40-4C was added after
blocking cells with rabbit sera, 
 
z
 
5 min before addition of anti-
bodies, and in a total volume of 100 
 
m
 
l. Cells were fixed with 1%
paraformaldehyde after staining and were kept on ice during en-
tire procedure. Cells were analyzed on a Becton Dickinson
(Mountain View, CA) FACScan
 
Ò
 
 using CellQuest software.
 
Results
 
ALX40-4C Blocks Virus Infection at the Level of Entry.
 
ALX40-4C (
 
N
 
-
 
a
 
-acetyl-nona-
 
d
 
-arginine (Arg) amide), a
polypeptide of nine Arg residues stabilized by terminal pro-
tection and inclusion of 
 
d
 
 amino acids, inhibits infection by
T-tropic virus strains at a step before reverse transcription
with an IC
 
50
 
 of 3 nM in the HUT78 T cell line and in
PBLs, but does not inhibit infection by M-tropic virus
strains (21). The region of HIV-1 responsible for this tro-
pism-specific inhibition localizes to the V3 loop of the Env
glycoprotein, but the mechanism of inhibition is undefined
(21). To further localize the effects of ALX40-4C, we used
luciferase reporter viruses based on a common NL4-3
HIV-1 core and pseudotyped with different Env proteins
(22). As a result, all reporter viruses are genetically identical
and have identical HIV-1 cores, so that postentry blocks
will affect all reporter viruses equally.
Reporter viruses pseudotyped with the T-tropic Envs
NL4-3 and HXB2 (that use CXCR4 as a coreceptor), the
M-tropic Env ADA (that uses CCR5), or the murine leu-
kemia virus (MLV) Env that enters cells independently of
CD4 or chemokine receptors, were used to infect PM1
cells, a T cell line that expresses CD4, CXCR4, and
CCR5 (6). As shown in Fig. 1 
 
A
 
, ALX40-4C inhibited in-
fection of viruses containing the NL4-3 and HXB2, but
not the ADA or MLV Envs. An antibody to CD4 inhibited
all HIV-1 strains tested. Inhibition of HXB2 infection in
PM1 cells was achieved with an IC
 
50
 
 of 
 
z
 
0.3 
 
m
 
M (data not
shown). Since ALX40-4C did not prevent infection by
ADA, we conclude that it did not block CD4 binding or
postentry steps of viral replication, suggesting that its inhib-
itory effects are at the level of virus entry and might be
coreceptor specific, consistent with involvement of the V3
loop in ALX40-4C sensitivity (21). To test this, we tran-
siently transfected feline cells that stably express human
CD4 with plasmids encoding the coreceptor of interest.
HIV-1 NL4-3 only infected cells expressing CXCR4,
whereas HIV-1 ADA only infected cells expressing CCR5
(Fig. 1 
 
B
 
). As with PM1 cells, ALX40-4C inhibited the en-
try of NL4-3, but did not significantly affect entry of ADA.
Figure 1. (A) Inhibition of virus infection on PM1 cells. The PM1 cell
line was infected with single-cycle pseudotyped HIV-1 virions and as-
sayed for luciferase production. (B) Feline CCCS1L-CD4 cells transiently
expressing either CXCR4 or CCR5 were infected with pseudotyped lu-
ciferase viruses. Results in both panels represent the average of two iden-
tical experiments using 10 mM ALX40-4C and 10 mg/ml Leu3A, and er-
ror bars represent the range of the two independent experiments. Relative
light unit (RLU) values are normalized to 100% for direct infection of
permissive cells. 
1397
 
Doranz et al. Brief Definitive Report
 
ALX40-4C Blocks Infection by Some Primary Virus Strains.
 
Previously, ALX40-4C was shown to inhibit infection of
PBLs by some primary virus strains (21). To examine this
in more detail, we tested the ability of ALX40-4C to in-
hibit infection of 10 primary virus strains. Of these, seven
formed syncytia on MT2 cells (SI isolates) which express
CXCR4 but not CCR5, whereas three did not form syn-
cytia (NSI isolates). ALX40-4C inhibited infection of human
PBMCs by three of seven SI strains, and did not inhibit the
three NSI strains (Table 1). Since a number of primary vi-
rus strains have demonstrated dual-tropic properties (5, 7,
24), the failure of ALX40-4C to inhibit all of the SI strains
in PBMCs could be due to use of alternative coreceptors such
as CCR5. Therefore, we tested the ability of ALX40-4C
to inhibit infection of MT2 cells (which do not express
CCR5) by the SI strains. In this system, six of seven pri-
mary SI strains were inhibited. Whether the single primary
SI strain that was not inhibited uses CXCR4 differently from
the other viruses or whether it uses an as yet unidentified
coreceptor present in MT2 cells is not known. Neverthe-
less, these results extend earlier findings and show that
ALX40-4C can inhibit CXCR4-dependent infection by
primary HIV-1 strains.
 
ALX40-4C Blocks HIV-1 Usage of CXCR4.
 
Although the
ability of ALX40-4C to block T-tropic, but not M-tropic
viruses at post-CD4 levels of entry implied blocking of core-
ceptor use, we could not distinguish if ALX40-4C blocked
the chemokine receptor directly or blocked regions of Env
that may mediate interactions with the chemokine recep-
tor. Therefore, we carried out infections with reporter viruses
containing dual-tropic Env proteins from the HIV-1 strains
89.6 and SF2. Both the HIV-1 89.6 and SF2 Env proteins
can mediate efficient membrane fusion in either a CXCR4-
or a CCR5-dependent manner. We found that ALX40-4C
inhibited infection by both viruses only when cells ex-
pressed CXCR4 (Fig. 2). CCR5-dependent virus infection
was not affected, indicating that the inhibitory effects of
ALX40-4C are CXCR4-dependent and are not directed at
the Env protein.
To confirm that the inhibitory effects we observed were
due to Env-mediated fusion events, we used a cell–cell fu-
sion assay that depends only on Env-mediated membrane
fusion for signal activity (7, 23). In this assay, murine
PA317-T4 cells which express human CD4, the coreceptor
of interest, and contain luciferase under control of the T7
promoter, are mixed with 293T cells that express the Env
protein of interest and T7 polymerase. Fusion of the two
cell populations results in cytoplasmic mixing and expres-
sion of luciferase. Use of the cell–cell fusion assay con-
firmed our infection results by demonstrating ALX40-4C
inhibition of fusion between cells expressing dual (89.6)
and T-tropic (BH8) Env proteins and cells expressing CD4
and CXCR4 (Fig. 3). Fusion between cells expressing
dual- and M-tropic (JR-FL) Env proteins and cells express-
ing CD4 and CCR5 was not significantly affected.
 
ALX40-4C Binds Directly to CXCR4.
 
Although ALX40-
4C inhibited CXCR4-dependent membrane fusion with
both T- and dual-tropic Env proteins, chemokine recep-
tors can be used differently by divergent virus strains, rais-
ing the possibility that ALX40-4C could interact with a re-
gion in a dual-tropic Env protein that mediates interactions
with CXCR4 without affecting its ability to use CCR5
(25–28). Thus, we tested its ability to prevent CXCR4 ac-
tivation by the chemokine stromal-derived factor (SDF)-1
 
a
 
and to prevent binding by an anti-CXCR4 monoclonal
antibody (12G5; reference 29). Binding of SDF-1
 
a
 
 to
CXCR4 results in intracellular G protein–mediated signals
that include Ca
 
2
 
1
 
 mobilization (13, 14). We found that
ALX40-4C, when incubated with SupT1 cells that express
CXCR4 and that normally respond to SDF-1
 
a
 
, was able
to eliminate Ca
 
2
 
1
 
 mobilization (Fig. 4 
 
A
 
). We also found
that incubation of SupT1 (Fig. 4 
 
B
 
), PM1 (not shown), or
 
Table 1.
 
ALX40-4C Inhibition of HIV-1 Replication
 
PBMC MT-2
Strain SI/NSI 1 
 
m
 
M 10 
 
m
 
M 10 
 
m
 
M
NL4-3 SI 85
 
.
 
95
 
.
 
95
1S I 4 2 8 5
 
.
 
95
2S I 7 3 9 0
3S I 7 3
 
.
 
95
 
.
 
90
5S I 2 0
 
.
 
95
6S I 5 7
 
.
 
95
 
.
 
95
7S I 1 0 6 0
10 SI 0 10
 
.
 
95
4 NSI 0 0 –
8 NSI 0 0 –
9 NSI 0 0 –
Human PBMCs or MT-2 cells were infected with 10 ng of the indicated
primary virus strains or with NL4-3 in the presence of either 1 
 
m
 
M or
10 
 
m
 
M ALX40-4C. The amount of viral p24 (60–150 ng/ml for PBMC,
160–450 ng/ml for MT2 cells) released into the supernatant was mea-
sured 7 d later. Percentage inhibition is indicated. NSI strains did not
grow on MT-2 cells.
Figure 2. Inhibition of CXCR4 coreceptor usage by dual-tropic Envs.
Luciferase virions were pseudotyped with envs from the primary, dual-
tropic virus 89.6 and from the lab-adapted strain SF2, both of which can
use CXCR4 and CCR5 for entry. Feline CCCS1L-CD4 cells transiently
expressing either CXCR4 or CCR5 were infected in the presence or ab-
sence of 10 mM ALX40-4C and results are presented as in Fig. 1. 
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293T cells (not shown) expressing CXCR4 with 10 
 
m
 
M
ALX40-4C completely inhibited binding of 12G5. Since
binding reactions were performed at 4
 
8
 
C, these results indi-
cate that ALX40-4C inhibited 12G5 binding directly rather
than by inducing receptor downregulation.
 
Discussion
 
ALX40-4C, a polypeptide of nine Arg residues stabilized
by terminal protection and inclusion of 
 
d
 
 amino acids, in-
hibits HIV-1 NL4-3 with an IC
 
50
 
 of 3 nM in the HUT78
T cell line and in PBLs (21). In this study, we found that
ALX40-4C inhibited entry of T-tropic, but not M-tropic
HIV-1 strains. ALX40-4C also inhibited primary dual-
tropic virus strains, but only when cells expressed CXCR4
alone. Infection of cells that express both CCR5 and
CXCR4 by dual-tropic virus strains was not inhibited by
ALX40-4C, likely reflecting the ability of these viruses to
use CCR5 when CXCR4 is blocked.
Addition of ALX40-4C to cells expressing CXCR4 pre-
vented SDF-1
 
a
 
–induced changes in intracellular calcium
and prevented binding of a monoclonal antibody, 12G5, to
cells expressing CXCR4. The epitope recognized by 12G5
resides in the first and second extracellular loops, the same
region of CXCR4 that is used by both dual- and T-tropic
HIV-1 strains (26, 30) and that overlaps with the activation
site of SDF-1
 
a
 
 (our unpublished results). These loops are
highly negatively charged, and so represent an obvious site
to which the cationic ALX40-4C can bind. It is interesting
to note that increasing numbers of basic residues in the V3
loop of Env play an important role in the shift from M to T
tropism (31, 32). Since the V3 region is implicated in core-
ceptor specificity and is the region of Env responsible for
sensitivity to ALX40-4C (21), it is tempting to speculate
that the V3 region of T- and dual-tropic Envs interacts
with the negatively charged first and second extracellular
loops of CXCR4, and that this interaction is prevented by
the polycationic compound ALX40-4C. Our results with
SDF-1
 
a
 
 and 12G5 suggest that ALX40-4C interacts di-
rectly with CXCR4. However, we cannot rule out the
possibility that ALX40-4C may also bind to other cell sur-
face molecules. Of note, ALX40-4C inhibits entry of her-
pes simplex virus type 1, a virus that is also sensitive to
other polycations (33).
The identification of chemokine receptors as potential
new antiviral targets is offset by the limitations of using
chemokine ligands therapeutically and by the variation in
susceptibility to chemokine inhibition of different strains of
HIV-1 (Trkola, A., and J.P. Moore, manuscript submit-
ted). ALX40-4C demonstrates the feasibility of developing
small-molecule antagonists to the chemokine receptors that
target a broad spectrum of HIV-1 strains that enter via a
specific chemokine receptor. The ability to inhibit T-tropic
HIV-1 strains may prove critically important in future treat-
ments since T-tropic strains of HIV-1 are associated with CD4
decline and progression to AIDS (34). In addition, under
conditions in which CCR5 is blocked, evolution of HIV-1
towards using CXCR4 could potentially be enhanced, thus
raising the possibility of hastening disease progression,
rather than delaying it. The use of a compound such as
ALX40-4C in conjunction with an anti-CCR5 compound
may avoid such pressures by targeting both major HIV-1
coreceptors.
Figure 3. Inhibition of cell–cell fusion. 293T cells expressing 89.6, JR-
FL, or BH8 Envs and T7 polymerase were mixed with PA317-T4 cells
expressing CD4, the coreceptor indicated, and a luciferase reporter gene
under control of a T7 promoter in the presence or absence of 10 mM
ALX40-4C. Fusion of the cell populations results in quantitative lu-
ciferase expression. Results are presented as in Fig. 1 with 89.6 normal-
ized to 100% for CXCR4.
Figure 4. ALX40-4C inhibits
interaction of SDF-1a and 12G5
with CXCR4. (A) Addition of
10–50 mM ALX40-4C inhib-
ited the response of SupT1 cells
to 500 ng/ml SDF-1a (Pepro-
tech) z90 s later. (B) Inhibition
of 12G5 binding. SupT1 cells
were stained with 12G5, a mono-
clonal antibody directed to
CXCR4, Leu3A, a monoclonal
antibody directed to CD4, or
mouse IgG. Binding of mono-
clonal antibodies and inhibition
by ALX40-4C was detected by
flow cytometry.
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